Business Of Biotech
Multimodal R&D Management with Incyte's Jim Lee, M.D., Ph.D.
Jan 22, 2024
In this podcast, Dr. Jim Lee, head of Inflammation and Autoimmunity at Incyte, discusses the company's multimodal approach to R&D. They explore the impact of a multimodal approach in drug development, specifically in dermatology. They also discuss the connection between inflammation, oncology, and dermatology, as well as their advancements in dermatology and future plans. Additionally, they touch on the role of biologics in dermatology and the impact of having a celebrity spokesperson for patient awareness. Dr. Lee concludes by discussing upcoming milestones in R&D.
50:31
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Insight Pharmaceuticals prioritizes patient-centric drug development, utilizing both small molecules and biologics to target various diseases.
- Data-driven decision making and a patient-oriented approach are key factors in Insight Pharmaceuticals' successful R&D management.
Deep dives
Insight's Multimodal Approach to Drug Development
Insight Pharmaceuticals takes a multimodal approach to drug development, prioritizing the patient and utilizing the best science. They focus on developing drugs for patients regardless of whether they are small molecules or biologics. By exploring diseases and potential targets, they determine the best approach for drug development. This approach has led to success in oncology, inflammation, blood disorders, GVHD, and their recent endeavor into dermatology. Insight structures its R&D function by clinical development, research, and chemistry, with a matrix team-based approach for project work.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
